VEGFA and neoplasm: Therefore, the purpose of this study was to undertake dual analysis of tumor perfusion and glucose metabolism after initiation of bevacizumab, a monoclonal antibody against the vascular endothelial growth factor, using perfusion CT and FDG-PET/CT in a VX2 tumor model in rabbits and to assess the possible added value of variable FDG-PET-derived indices to perfusion CT in monitoring early treatment response.